Successful kick-off for large clinical study with EGb 761® in China
2025-07-21
We are pleased to announce that, under the scientific direction of the renowned researcher Prof. Yongjun Wang, we have successfully kicked-off a large clinical trial with our Ginkgo biloba special extract EGb 761® in patients with cognitive impairment after stroke in China (GiCIIS - Ginkgo Biloba in Cognitive Impairment after an acute Ischemic Stroke). Professor Wang heads China National Clinical Research Center for Neurological Diseases, which establishes treatment standards for neurological diseases in China. The center is based at Beijing Tiantan Hospital affiliated to the Capital Medical University.
As part of the 11th Annual Scientific Session of Chinese Stroke Association & TISC 2025, the investigators’ meeting for the study was attended by over 80 leading researchers from 45 medical centers across China and was meticulously planned and conducted by a scientific team from Tiantan Hospital. The meeting covered the latest advances and experiences from clinical practice in the treatment of cognitive impairment after stroke, and the planned study was discussed in detail.
Provide new, evidence-based medical data for the treatment of cognitive impairment after stroke
The aim of this study is to provide new, evidence-based medical data for the treatment of cognitive impairment after stroke, with a view to offer affected patients effective, scientifically proven treatment options. The speakers emphasized the value and clinical significance of new study data. Cognitive impairment is a common complication in stroke patients, with an incidence rate of up to 80% following a stroke.
The study will enroll 400 patients. All patients will receive standard treatment and will be followed for a period of one year. Patients will be randomly assigned to two groups: Standard treatment alone or standard treatment plus additional treatment with Ginkgo biloba special extract EGb 761®.
Photo caption: Prof. Yongjun Wang (4th from left) and his team — Prof. Beibei Xu, Prof. Xia Meng, and Prof. Jiong Shi (left to right) — together with our colleagues Dr. Dirk Bredenbröker, MD (5th from left), Petra Klement, Dr. Marilia Soria, and Anne-Katrin Maly (left to right) at Capital Medical University in Beijing, China.